# A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

> **NCT05184816** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Leptomeningeal Metastases

## Interventions

- **DRUG:** Deferoxamine (DFO)

## Key facts

- **NCT ID:** NCT05184816
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-22
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184816, "A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05184816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*